NSD1

Across TCGA pan-cancer cohorts, NSD1 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated NSD1 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher NSD1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated NSD1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

ACC, UCEC, and LIHC are the cancer types where NSD1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.010	0.667	<.001	45	view →
UCEC	DFS	Median	II,III,IV	0.909	0.418	.003	22	view →
LIHC	DFS	Median	II,III,IV	0.044	0.414	<.001	9	view →
STAD	DFS	Median	All	0.292	0.713	.012	6	view →
LUSC	DFS	Median	II,III,IV	0.199	0.748	.006	5	view →
BLCA	DFS	Median	III,IV	0.534	0.264	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

NSD1–ACC (DFS)

Open the ACC breakdown →